What is Leerink Partnrs’ Forecast for CGEM FY2025 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Equities researchers at Leerink Partnrs lifted their FY2025 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($4.11) per share for the year, up from their prior estimate of ($4.16). The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ FY2026 earnings at ($3.06) EPS and FY2027 earnings at ($0.06) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.09.

A number of other research analysts have also weighed in on the company. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. Finally, UBS Group initiated coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $30.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.67.

Cullinan Therapeutics Stock Down 2.6 %

NASDAQ:CGEM opened at $13.10 on Wednesday. Cullinan Therapeutics has a 12-month low of $7.64 and a 12-month high of $30.19. The firm has a market capitalization of $762.79 million, a price-to-earnings ratio of -4.61 and a beta of -0.12. The stock’s 50 day moving average price is $16.35 and its two-hundred day moving average price is $18.58.

Hedge Funds Weigh In On Cullinan Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Cullinan Therapeutics by 31.0% in the first quarter. Ameritas Investment Partners Inc. now owns 2,599 shares of the company’s stock valued at $44,000 after acquiring an additional 615 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Cullinan Therapeutics by 3.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,842 shares of the company’s stock valued at $390,000 after purchasing an additional 820 shares in the last quarter. Amalgamated Bank increased its stake in shares of Cullinan Therapeutics by 97.3% in the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock valued at $30,000 after purchasing an additional 872 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Cullinan Therapeutics by 3.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,911 shares of the company’s stock worth $1,187,000 after buying an additional 2,377 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Cullinan Therapeutics by 73.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company’s stock worth $155,000 after buying an additional 3,758 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cullinan Therapeutics

In related news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $15.64, for a total value of $125,120.00. Following the completion of the transaction, the insider now owns 107,942 shares of the company’s stock, valued at $1,688,212.88. The trade was a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.07% of the stock is currently owned by corporate insiders.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.